Ten reasons to use fentanyl Review article
Article Sidebar
Published:
Feb 6, 2023
Keywords:
fentanyl, pain, breakthrough cancer pain, transdermal system, transmucosal system
Main Article Content
Abstract
In patients with chronic, incurable diseases, including cancer, the most important goal is to control symptoms, improving the quality of life. One of the most important symptoms is pain. About 15–75% of oncological patients suffer from pain, caused by the disease itself or it’s treatment. WHO guidelines show opioids as the most important group of medications. Fentanyl requires special consideration among them, because of it’s different, possible ways of use-parenteral, transdermal and transmucosal and because of it’s high efficacy in breakthrough cancer pain treatment.
Article Details
How to Cite
Pełka-Zakielarz, J. (2023). Ten reasons to use fentanyl. Medycyna Faktow (J EBM), 1-4. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2529
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Ciałkowska-Rysz A, Dzierżanowski T. Medycyna paliatywna. Termedia, Poznań 2019.
2. McIntyre IM, Anderson DT. Postmortem fentanyl concentration: a review. J Forensic Res. 2012;
3: 1-10. 3. Bista SR, Haywood A, Hardy J et al. Protein binding of fentanyl and its metabolite nor-fentanyl in human plasma, albumin and α-1 acid glycoprotein. Xenobiotica. 2015; 45: 207-12.
4. Mercadante S, Cuomo A. Breakthrough Cancer Pain: Ten Commandments. Value Health. 2016; 19: 531-6.
5. Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev. 2013; (10): CD004311.
6. Woroń J. Farmakoterapia u kresu życia. Onkologia po Dyplomie. 2019; 16(4): 17-21.
7. Novotna S, Valentova K, Fricova J et al. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. Clin Ther. 2014; 36(3): 357-67.
8. Charakterystyka produktu leczniczego dla preparatów Instanyl i PecFent.
9. Davies A. A New Fast-acting Sublingual Fentanyl (Recivit®) for Treating Breakthrough Cancer Pain. Eur Oncol Haematol. 2014; 10(1): 12-6.
10. Charakterystyka produktu leczniczego dla preparatów Vellofent, Effentora, Aurofena.
11. Wordliczek J, Zajączkowska R, Woroń J. Leczenie bólu u chorych na nowotwory. PZWL, Warszawa 2020: 41-2.
12. Davies A. Cancer-related Breakthrough Pain (3rd ed). May 2019 Oxford University.
13. Guitart J, Vargas MI, De Sanctis V et al. Breakthrough pain management with sublingual fentanyl tablets in patients with cancer: age subgroup analysis of a multicenter prospective study. Drugs RD. 2017; 17(3): 419-25
14. Guitart J, Vargas MI, De Sanctis V et al. Effects of age among elderly cancer patients on breakthrough pain management with sublingual fentanyl tablets. Drugs RD. 2019; 19(3): 247-54.
15. England R, Maddocks M, Manderson C et al. How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion. BMJ Support Palliat Care. 2011; 1: 349-51.
16. Janecki M. Zastosowanie podjęzykowych tabletek fentanylu w leczeniu incydentalnego bólu przebijającego u chorej z zaawansowaną chorobą nowotworową – opis przypadku. Medycyna Paliatywna. 2017; 9(2): 110-4.
17. Lennernäs B, Frank-Lissbrant I, Lennernäs H et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliat Med. 2010; 24: 286-93.
18. Rauck RL, Tark M, Reyes E et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009; 25: 2877-85.
19. Shimoyama N, Gomyo I, Katakami N et al. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial. Int J Clin Oncol. 2015; 20: 198-206.
20. Shimoyama N, Gomyo I, Teramoto O et al. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain. Jpn J Clin Oncol. 2015; 45: 189-96.
21. Zeppetella G, Davies A, Eijgelshoven I et al. A Network Meta Analysis of the Efficacy of Opioid Analgesics for the Management of Breakthrough Cancer Pain Episodes. J Pain Symptom Manage. 2014; 47: 773-85.
22. Defraeye T, Bahrami F, Ding L et al. Predicting Transdermal Fentanyl Delivery Using Mechanistic Simulations for Tailored Therapy. Front Pharmacol. 2020; 11: 585393.
2. McIntyre IM, Anderson DT. Postmortem fentanyl concentration: a review. J Forensic Res. 2012;
3: 1-10. 3. Bista SR, Haywood A, Hardy J et al. Protein binding of fentanyl and its metabolite nor-fentanyl in human plasma, albumin and α-1 acid glycoprotein. Xenobiotica. 2015; 45: 207-12.
4. Mercadante S, Cuomo A. Breakthrough Cancer Pain: Ten Commandments. Value Health. 2016; 19: 531-6.
5. Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev. 2013; (10): CD004311.
6. Woroń J. Farmakoterapia u kresu życia. Onkologia po Dyplomie. 2019; 16(4): 17-21.
7. Novotna S, Valentova K, Fricova J et al. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. Clin Ther. 2014; 36(3): 357-67.
8. Charakterystyka produktu leczniczego dla preparatów Instanyl i PecFent.
9. Davies A. A New Fast-acting Sublingual Fentanyl (Recivit®) for Treating Breakthrough Cancer Pain. Eur Oncol Haematol. 2014; 10(1): 12-6.
10. Charakterystyka produktu leczniczego dla preparatów Vellofent, Effentora, Aurofena.
11. Wordliczek J, Zajączkowska R, Woroń J. Leczenie bólu u chorych na nowotwory. PZWL, Warszawa 2020: 41-2.
12. Davies A. Cancer-related Breakthrough Pain (3rd ed). May 2019 Oxford University.
13. Guitart J, Vargas MI, De Sanctis V et al. Breakthrough pain management with sublingual fentanyl tablets in patients with cancer: age subgroup analysis of a multicenter prospective study. Drugs RD. 2017; 17(3): 419-25
14. Guitart J, Vargas MI, De Sanctis V et al. Effects of age among elderly cancer patients on breakthrough pain management with sublingual fentanyl tablets. Drugs RD. 2019; 19(3): 247-54.
15. England R, Maddocks M, Manderson C et al. How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion. BMJ Support Palliat Care. 2011; 1: 349-51.
16. Janecki M. Zastosowanie podjęzykowych tabletek fentanylu w leczeniu incydentalnego bólu przebijającego u chorej z zaawansowaną chorobą nowotworową – opis przypadku. Medycyna Paliatywna. 2017; 9(2): 110-4.
17. Lennernäs B, Frank-Lissbrant I, Lennernäs H et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliat Med. 2010; 24: 286-93.
18. Rauck RL, Tark M, Reyes E et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009; 25: 2877-85.
19. Shimoyama N, Gomyo I, Katakami N et al. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial. Int J Clin Oncol. 2015; 20: 198-206.
20. Shimoyama N, Gomyo I, Teramoto O et al. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain. Jpn J Clin Oncol. 2015; 45: 189-96.
21. Zeppetella G, Davies A, Eijgelshoven I et al. A Network Meta Analysis of the Efficacy of Opioid Analgesics for the Management of Breakthrough Cancer Pain Episodes. J Pain Symptom Manage. 2014; 47: 773-85.
22. Defraeye T, Bahrami F, Ding L et al. Predicting Transdermal Fentanyl Delivery Using Mechanistic Simulations for Tailored Therapy. Front Pharmacol. 2020; 11: 585393.